August, 2018
HD Featured in Science Magazine
Posted on August 30, 2018
The prestigious Science magazine published an article on Huntington’s disease this week, describing the huntingtin-lowering ASO drug developed by Ionis,…
Read MoreProposal to Streamline Gene Therapy Evaluation by the FDA
Posted on August 23, 2018
This week, the FDA released a proposal to streamline the way they oversee the evaluation of protocols related to gene…
Read MoreFirst Gene-Silencing Drug Approved by the FDA
Posted on August 16, 2018
This week marked the first FDA approval of a gene silencing drug, for a rare hereditary disease called ATTR amyloidosis….
Read MoreRoche Huntingtin-Lowering Drug Gains PRIME Status from EMA
Posted on August 7, 2018
On August 4th, Roche Pharmaceuticals announced that their huntingtin-lowering therapy was granted PRIME status from the European Medicines Agency (EMA)….
Read MoreVoice Your Opinions About The Future Of CRISPR
Posted on August 2, 2018
Community research surveys are valuable ways for researchers to get input from HD patients, families and caregivers about a variety…
Read More